From the listed options, CXCL10 and CXCR3 are the characteristics of NSCLC while receptor for advanced glycation end products (RAGE) and its ligand, high mobility group box-1 protein (HMGB1) could contribute discretely in activating the immuno and chemotherapy. Here, AGER is linked to non-small cell lung carcinoma.